

GNE-783

Chemical Properties


CAS No. : 1200127-66-7

Formula: C₂₂H₂₀N₆

Molecular Weight: 368.43

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	GNE-783 is a highly selective CHK1 inhibitor that effectively enhances the antitumor efficacy of gemcitabine. After DNA damage, it inactivates S-phase and G2-phase cell cycle checkpoints, thereby improving the therapeutic effect of antimetabolite DNA-damaging agents. GNE-783 shows selective chemosensitization in different tumors, such as enhancing the antitumor activity of temozolomide only in melanoma cell lines.
Targets(IC50)	Chk

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.7142 mL	13.5711 mL	27.1422 mL
5 mM	0.5428 mL	2.7142 mL	5.4284 mL
10 mM	0.2714 mL	1.3571 mL	2.7142 mL
50 mM	0.0543 mL	0.2714 mL	0.5428 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor

Gazzard L, Appleton B, Chapman K, Chen H, Clark K, Drobnick J, Goodacre S, Halladay J, Lyssikatos J, Schmidt S, Sideris S, Wiesmann C, Williams K, Wu P, Yen I, Malek S. Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1. *Bioorg Med Chem Lett*. 2014 Dec 15;24(24):5704-5709. doi: 10.1016/j.bmcl.2014.10.063. Epub 2014 Oct 27. PubMed PMID: 25453805.

Del Nagro CJ, Choi J, Xiao Y, Rangell L, Mohan S, Pandita A, Zha J, Jackson PK, O'Brien T. Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death. *Cell Cycle*. 2014;13(2):303-14. doi: 10.4161/cc.27055. Epub 2013 Feb 1. PubMed PMID: 24247149; PubMed Central PMCID: PMC3906246.

Xiao Y, Ramiscal J, Kowanetz K, Del Nagro C, Malek S, Evangelista M, Blackwood E, Jackson PK, O'Brien T. Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor. *Mol Cancer Ther*. 2013 Nov;12(11):2285-95. doi: 10.1158/1535-7163.MCT-13-0404. Epub 2013 Sep 13. PubMed PMID: 24038068.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481